ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported 2024 results sharing progress with ...

Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Greetings, and welcome to the Achieve Life Sciences Fourth Quarter ...

Reiterated plans for NDA submission for cytisinicline ... with the FDA to confirm alignment on the proposed Phase 3 study design. The FDA agreed that one well-controlled Phase 3 trial (ORCA ...

Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is ...

The post A Real-Life White Lotus! $48 Million Florida Smart Home With Private Wellness Center and Signature Scent Puts HBO's ...

Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, ...

The Shri Ram Universal School, in collaboration with the Nations Development Association (NDA) organized ‘Viksit Yuva Samelan ...

Odisha Assembly was adjourned twice on Thursday due to a din created by Opposition BJD MLAs over the controversial Polavaram ...

Ocular Therapeutix Q4 2024 earnings reveal FDA-approved trial updates for AXPAXLI in wet AMD, streamlined designs, and strong cash reserves.

James Caruso; President, Chief Executive Officer, Director; Cellectar Biosciences Inc. Chad Kolean; Chief Financial Officer, Vice ...

Defence Minister Rajnath Singh on Sunday asserted that the aerospace sector is going to witness an unprecedented growth in ...